Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Celgosivir (MDL 28,574A) in HIV
NCT00002150Phase 2Completed
- Sponsor
- Hoechst Marion Roussel
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of celgosivir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Hoechst Marion Roussel. Primary endpoints: Safety of MDL 28,574A and Efficacy of MDL 28,574A. Status: completed.
02
Drugs
celgosivir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00002150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002150.